|
|
|
Insider
Information: |
Desilva Nishan M |
Relationship: |
Director |
City: |
Westminster |
State: |
CO |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
3 |
|
Direct
Shares |
242,282 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$5,201,748 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
242,282 |
|
|
Total
Value |
$5,201,748 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Allos Therapeutics Inc |
ALTH |
Director |
2011-12-13 |
35,000 |
2011-12-13 |
0 |
Premium* |
|
Ligand Pharmaceuticals Inc |
LGND |
VP, Finance & Strategy... |
2015-05-14 |
22,282 |
2012-12-31 |
0 |
Premium* |
|
Cartesian Therapeutics, Inc |
RNAC |
Director |
2024-01-02 |
185,000 |
2021-12-02 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
15 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
RNAC |
Cartesian Therapeutics, I... |
Director |
|
2021-12-02 |
4 |
B |
$2.96 |
$20,723 |
D/D |
7,000 |
7,000 |
2.39 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Corporate Development |
|
2012-12-31 |
4 |
A |
$14.54 |
$7,122 |
D/D |
490 |
10,490 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Corporate Development |
|
2013-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
15,490 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Corporate Development |
|
2013-06-28 |
4 |
B |
$17.36 |
$2,934 |
D/D |
169 |
15,659 |
2.66 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Corporate Development |
|
2015-02-10 |
4 |
S |
$56.34 |
$129,582 |
D/D |
(2,300) |
16,359 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Corporate Development |
|
2014-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
18,659 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Corporate Development |
|
2015-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
5,923 |
22,282 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Finance & Strategy and CFO |
|
2015-05-12 |
4 |
S |
$84.44 |
$1,990,403 |
D/D |
(23,520) |
22,282 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Finance & Strategy and CFO |
|
2015-05-13 |
4 |
S |
$83.23 |
$1,990,671 |
D/D |
(23,905) |
22,282 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Finance & Strategy and CFO |
|
2015-05-14 |
4 |
S |
$83.84 |
$1,755,442 |
D/D |
(20,938) |
22,282 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Finance & Strategy and CFO |
|
2015-05-12 |
4 |
OE |
$14.47 |
$409,664 |
D/D |
23,520 |
31,588 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Finance & Strategy and CFO |
|
2015-05-13 |
4 |
OE |
$14.47 |
$436,408 |
D/D |
23,905 |
34,039 |
0 |
- |
|
ALTH |
Allos Therapeutics Inc |
Director |
|
2011-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
35,000 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
VP, Finance & Strategy and CFO |
|
2015-05-14 |
4 |
OE |
$74.42 |
$1,558,206 |
D/D |
20,938 |
43,220 |
0 |
- |
|
RNAC |
Cartesian Therapeutics, I... |
Director |
|
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
178,000 |
185,000 |
0 |
- |
|
15 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|